bet bromdomains Bromodomain and extraterminal domain (BET) proteins - JQ1BETinhibitor BET proteins contain two separate bromodomains Understanding BET Bromodomains: Key Regulators of Gene Expression and Therapeutic Targets

What areBETproteins BET bromodomains are integral components of the cellular machinery that regulates gene expression, and their dysregulation is increasingly linked to various diseases, particularly cancer.BET Proteins as Targets for Anticancer Treatment The Bromodomain and Extra-Terminal domain (BET) family of proteins, which includes BRD2, BRD3, BRD4, and BRDT, are characterized by the presence of two tandem bromodomains and an extra-terminal domain.作者：AP Cribbs·2021·被引用次数：26—We show thatboth BRD2 and BRD4 control inflammatory cytokine productionin NK cells isolated from healthy volunteers and from rheumatoid arthritis patients. These bromodomains, often referred to as epigenetic "readers" of acetylated lysine marks, play a crucial role in interpreting the epigenetic landscape of a cell.Discovery of potent BET bromodomain 1 stereoselective ... This article delves into the function of BET proteins, explores the therapeutic potential of BET bromodomain inhibitors, and highlights recent advancements in the field, providing a comprehensive overview for researchers and clinicians interested in this rapidly evolving area of studyTargeting BET Bromodomains for Cancer Treatment.

The Fundamental Role of BET Proteins and Bromodomains

At their core, BET proteins are transcriptional regulators. Their bromodomains enable them to bind to acetylated histones, thereby recruiting chromatin-modifying complexes to specific genomic loci. This interaction is fundamental to the process of transcription initiation and elongation, effectively dictating which genes are expressed and at what levels. The BET (Bromodomain and extraterminal domain) family is a prime example of how these protein structures function. BRD2 and BRD4, in particular, have been extensively studied for their roles in controlling transcription.作者：KKW To·2023·被引用次数：96—They are linked to cancer progressiondue to their interaction with numerous cellular proteins including chromatin-modifying factors, transcription factors, and ... Research by Modukuri et al. (2022) and Filippakopoulos et al. (2010) has underscored that BET bromodomain inhibition can be therapeutic in multiple diseases. Furthermore, studies like those by Cribbs et al.BET Proteins as Targets for Anticancer Treatment (2021) demonstrate that both BRD2 and BRD4 control inflammatory cytokine production, revealing their significant involvement in immune responses and highlighting that BET bromodomain proteins play a significant role in regulating the inflammatory responses stimulated by various cues.

BET Inhibitors: A Promising Therapeutic Avenue

The critical role of BET proteins in driving aberrant gene expression programs, especially in cancer, has spurred the development of BET bromodomain inhibitors. These molecules are designed to interfere with the binding of BET proteins to acetylated histones, thereby downregulating the expression of oncogenes and other disease-associated transcriptional targets作者：ZQ Wang·2023·被引用次数：180—BET proteins, which influence gene expression and contribute to the development of cancer, are epigenetic interpreters.. The concept of BET bromodomain inhibition being a therapeutic strategy has gained significant traction over the past decade, with numerous small-molecule inhibitors being developed and evaluated.

Early breakthroughs, such as the discovery of JQ1, reported by Filippakopoulos et al. (2010), demonstrated the potential of competitive binding to bromodomainsPotent and selective bivalent inhibitors of BET bromodomains. Subsequently, a new generation of BET bromodomain inhibitors has emerged, moving beyond pan-BET inhibition to selectively target individual bromodomains, such as BET-BD1 or BET-BD2. This selectivity offers distinct advantages by potentially reducing off-target effects and improving therapeutic outcomes. For instance, BET bromodomain inhibitor 1 is described as an orally active, selective inhibitor with a potent IC50 for BRD4.BET bromodomain inhibitor Similarly, I-BET 762 is a potent and high-affinity BET bromodomain inhibitor, with reported IC50 values in the nanomolar range.

The Link Between BET Proteins and Disease Progression

They are linked to cancer progression due to their interaction with numerous cellular proteins, including chromatin-modifying factors and transcription factors. Dysregulation of BET proteins is implicated in a wide array of malignancies, including hematological cancers like leukemia and lymphoma, as well as solid tumorsA Minireview on BET Inhibitors: Beyond Bromodomain .... By modulating gene expression critical for cell proliferation, survival, and metastasis, BET proteins become key drivers of oncogenesis.作者：KKW To·2023·被引用次数：96—The mammalian bromodomain and extra-terminal domain (BET) family of proteins consists of four conserved members (Brd2, Brd3, Brd4, and Brdt) ... The development of BET bromodomain inhibitors therefore represents a direct approach to target these drivers for therapeutic benefit. Studies such as those by Jung et al. (2015) have reviewed the significance of BET bromodomain proteins as targets for various pathologies, predominantly cancer.

Beyond cancer, research is also exploring the role of BET proteins in other diseases.BET Bromodomain Inhibitors: Novel Design Strategies and ... For example, the role of BET bromodomain proteins in regulating inflammatory responses is an active area of investigation, suggesting potential applications in treating autoimmune and inflammatory conditions. Furthermore, BET bromodomain degradation through HPP-9 results in prolonged Hh pathway inhibition, indicating newer therapeutic strategies beyond simple inhibition.

Exploring Novel Strategies and Future Directions

The field of BET bromodomain inhibitor research is continuously evolving. Recent advances focus on novel design strategies, including the development of selective inhibitors and bivalent inhibitors that bind to BET proteins' two separate bromodomains in a unique way. Waring et al. (2016) described the discovery of potent and selective bivalent inhibitors. The exploration of targeting non-BET bromodomains is also emerging as an area of opportunity, moving beyond the well-studied BET (Bromodomain and extraterminal domain) family.作者：P Filippakopoulos·2010·被引用次数：4891—Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, orbromodomains.

While significant progress has been made, challenges remain. These include optimizing drug efficacy, managing potential side effects such as myelosuppression associated with some pan-BET inhibitors, and developing biomarkers to identify patients most likely to respond to BET bromodomain inhibitorsThe present invention providesBET bromodomain inhibitors, as exemplified by compounds of structural formula (I), for the treatment of a variety of diseases and .... Nevertheless, the potential of BET bromodomain inhibitors as anticancer and anti-inflammatory drug candidates is immenseTargeting BET Bromodomains in Cancer. Bromodomains, epigenetic “readers” of acetylated lysine marks, represent promising therapeutic targets, and continued research into understanding the intricate functions of BET proteins and developing more refined inhibitors will be critical in translating this promise into clinical reality.Recent advances and strategies in BET bromodomain ... The diverse applications and ongoing research, including the comprehensive understanding presented by Ali et al. (2020) on BET bromodomains, pave the way for future therapeutic breakthroughs. The ultimate goal is to harness the power of BET bromodomain inhibitors to improve patient outcomes in a range of debilitating diseasesBromodomain Inhibitor - an overview | ScienceDirect Topics.